Research

Cure SMA Holds Patient-Led Listening Session with FDA

October 4, 2022
Posted in , ,

On Thursday, August 4, 2022, six members of the SMA community had the opportunity to talk directly with the U.S. Food and Drug Administration (FDA) […]

Read More ›

Cure SMA Launches Benefit-Risk Survey to Assess Patient Perspective on Treatment Possibilities and Risks

September 8, 2022
Posted in , ,

Cure SMA is conducting a survey to understand our community’s perspectives on treatment possibilities and tolerance for the side effects of currently available and planned […]

Read More ›

2022 Cure SMA Annual Research Meeting Summaries – Special and Clinical Research Session

August 15, 2022
Posted in , ,

In June, SMA researchers and clinicians from around the world met in Anaheim, CA, for the 2022 Annual SMA Research and Clinical Care Meeting. There […]

Read More ›

2022 Cure SMA Annual Research Meeting Summaries – Basic Research Sessions

August 15, 2022
Posted in , ,

In June, SMA researchers and clinicians from around the world met in Anaheim, CA, for the 2022 Annual SMA Research and Clinical Care Meeting. There […]

Read More ›

Cure SMA Advocacy Campaign Leads to Congressional Support for More SMA Research

August 3, 2022
Posted in , ,

Congress has recognized the unmet and new needs of individuals with SMA by including legislative language in must-pass legislation asking the National Institutes of Health […]

Read More ›

Cure SMA to Hold Patient-Led Listening Session with FDA

August 1, 2022
Posted in ,

On Thursday, August 4, 2022, six members of the SMA community will have the opportunity to talk directly with the U.S. Food and Drug Administration […]

Read More ›

Cure SMA Attends Spring 2022 Conferences to Promote Findings from Industry Collaboration Initiatives

June 9, 2022
Posted in ,

Cure SMA is pleased to announce the participation of scientific leadership in the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13–16, 2022), […]

Read More ›

FDA Approves Genentech’s Evrysdi (risdiplam) For Use in Babies Under Two Months with Spinal Muscular Atrophy

May 31, 2022
Posted in , ,

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to […]

Read More ›

Cure SMA Launches Request for Proposals for SMA Research Projects and Postdoctoral Fellowships

April 18, 2022
Posted in , ,

Cure SMA is pleased to announce that we are accepting grant applications for funding of research projects and postdoctoral fellowships, under a competitive review by […]

Read More ›

Cure SMA Announces Expanded Phase 7 of SMA Industry Collaboration

March 23, 2022
Posted in , ,

Cure SMA is pleased to announce the launch of an expanded Phase 7 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted […]

Read More ›
Scroll to Top